Back to search
Publication

Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept.

Abstract

Erythema nodosum leprosum (ENL), or type II reaction, is a common complication of lepromatous leprosy that can cause significant patient debility. First-line therapy includes prednisone and thalidomide, with clofazimine reserved for patients who do not respond to first-line treatment. We present the case of a 33-year-old woman with ENL that failed to respond adequately to conventional therapy over a 6-year period. Because of the severe nature of her disease and the adverse effects of therapy that she experienced, a trial of etanercept was undertaken, which led to full resolution of her ENL. The rationale behind our choice of therapy and its future implications are discussed.

More information

Type
Journal Article
Author
Ramien ML
Wong A
Keystone JS
Year of Publication
2011
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume
52
Issue
5
Number of Pages
e133-5
Date Published
2011 Mar 01
Language
eng
ISSN Number
1537-6591
DOI
10.1093/cid/ciq213
Alternate Journal
Clin. Infect. Dis.
Publication Language
eng